Clinical Trials Browser

Neoplasm, Residual × Immunotherapy × 30 days × Clear all

NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male